You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
減肥藥Wegovy生產商諾和諾德市值單日蒸發700億美元
阿思達克 07-30 11:43
減肥藥Wegovy生產商諾和諾德(總部位於丹麥)昨日(29日)發布盈警及宣布委任新行政總裁,股價一度挫近三成,收市仍跌逾兩成,市值單日蒸發700億美元。 公司削減今年銷售增長展望,由介乎13%至21%降至介乎8%至14%。公司的減肥藥Wegovy及糖尿病藥Ozempic面對仿製藥影響。美國法律禁止複製已批准藥物,但允許為需要定制劑量或配方的患者進行「複方配製」。 該股去年高峰時估值曾達6,150億美元,現股價較去年高位跌三分二,單計今年累跌逾44%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account